Safety and Efficacy of Vocacapsaicin for Management of Postsurgical Pain: A Randomized Clinical Trial
Primary result · Pain at rest (NRS AUC)Result — go to the resultReduction 33% 95% CI 10%–52%Authors' conclusion
A single, local administration of vocacapsaicin during surgery reduced pain and opioid consumption for at least 96 h after surgery compared to control.
Study context
- Population
- Patients undergoing bunionectomyrandomised 1:1:1:1
- Participants
- 147 patients
- Comparison
- Surgical site vocacapsaicin 0.30, 0.15 or 0.05 mg/ml vs placebo
- Primary endpoint
- AUC of NRS pain score at rest, 0.30 mg/ml group
- Follow-up
- Through 96 h
Methodological detailstriple-blinded, placebo-controlled, dose-ranging
- Triple-blinded
- Placebo-controlled
- Dose-ranging
Primary result
Pain at rest (NRS AUC) · first 96 h
Reduction
33%
95% CI 10%–52%
P = 0.005
As reported in the abstract
Secondary outcomes
| Outcome | Placebo | 0.30 mg/ml | Reduction (95% CI) | P value |
|---|---|---|---|---|
| No postoperative opioids required · 0 to 96 h0.30 mg/ml vs Placebo | 5% | 26% | P = 0.025 | |
| Opioid consumption · first 96 h0.30 mg/ml vs Placebo · effect size = 0.76 | 50% (26%–67%) | P = 0.002 | ||
| Pain (NRS AUC) · first week0.30 mg/ml vs Placebo · effect size = 0.62 | 37% (12%–57%) | P = 0.004 |
Duration and dose-response
- Treatment effect persisted for at least 2 weeks
- All endpoints showed a concentration-versus-response relationship
Safety
- Well tolerated; no differences between groups in any safety parameter
Original publication
Safety and Efficacy of Vocacapsaicin for Management of Postsurgical Pain: A Randomized Clinical Trial. Anesthesiology. Published 25 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →